Clinical Trials Logo

Venous Thrombosis clinical trials

View clinical trials related to Venous Thrombosis.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06319131 Not yet recruiting - Clinical trials for Portal Vein Thrombosis

Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the comparative effectiveness of nadroparin versus transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory asymptomatic portal vein thrombosis using a design of a multicenter, randomized controlled trial

NCT ID: NCT06318754 Not yet recruiting - Thrombosis Clinical Trials

Large-Bore Mechanic Thrombectomy for the Treatment of Symptomatic Portomesenteric Vein Thrombosis

Start date: June 2024
Phase:
Study type: Observational

A single site study evaluating the safety, feasibility, and effectiveness of percutaneous large-bore mechanical thrombectomy using the Inari Triever Aspiration Catheter for the treatment of portomesenteric vein thrombosis (PMVT).

NCT ID: NCT06288906 Not yet recruiting - Thrombosis, Venous Clinical Trials

Acute and Subacute Iliofemoral and/or Caval Deep Vein Thrombosis: Evaluation of Mechanical Thrombectomy Systems

ASTER
Start date: March 30, 2024
Phase:
Study type: Observational

This is a physician-initiated, observational, monocentric, retrospective and prospective Study. The study is intended to assess the feasibility of mechanical thrombectomy of caval and iliofemoral veins according to normal clinical practice in adult patients with symptomatic acute or subacute ileofemoral or caval deep vein thrombosis objectively diagnosed with CT scan imaging.

NCT ID: NCT06232551 Not yet recruiting - Clinical trials for Deep Vein Thrombosis

Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

eVTE
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal. The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low. The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.

NCT ID: NCT06195540 Not yet recruiting - Pulmonary Embolism Clinical Trials

RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing

RIVACAST
Start date: May 31, 2024
Phase: Phase 3
Study type: Interventional

Lower limb trauma requiring immobilization is a very frequent condition that is associated with an increased risk of developing venous thromboembolism (VTE). The TRiP(cast) score has been developed to provide individual VTE risk stratification and help in thromboprophylactic anticoagulation decision. The recent CASTING study had confirmed that patients with a TRiP(cast) score <7 have a very low risk of VTE and could be safely manage without prophylactic treatment. Conversely, patients with a score ≥ 7 have a high-risk of VTE and require a prophylactic anticoagulant treatment. Low molecular weight heparins (LMWH) have been shown to be effective in this indication. However, in the CASTING study, the 3-month symptomatic VTE rate was 2.6% in this subgroup despite LMWH prophylactic treatment. This result suggests that LMWH are not sufficiently effective in this particular subgroup of high-risk patients. Direct oral anticoagulants, and in particular rivaroxaban, may be an effective and safe alternative to LMWH. In the PRONOMOS study, comparing LMWH with rivaroxaban in patients who had undergone non-major lower limb surgery, the relative risk of symptomatic VTE was 0.25 (95% CI = 0.09 - 0.75) in favor of rivaroxaban 10mg. No significant increase in bleeding was found. In addition, as LMWH treatment requires subcutaneous daily injections, the use of rivaroxaban may positively impact patients' quality of life as well as being effective in medico-economic terms. The aims of this study are to demonstrate that rivaroxaban is at least as effective, easier to use and more efficient than LMWH in patients with trauma to the lower limb requiring immobilisation and deemed to be at risk of venous thromboembolism (TRiP(cast) score ≥ 7). High-risk patients are randomized to receive either rivaroxaban or LMWH. They are followed up at 45 days and 90 days to assess the occurrence of thrombotic events or bleeding, as well as their satisfaction with the treatment received.

NCT ID: NCT06150807 Not yet recruiting - Clinical trials for Portal Vein Thrombosis

Portal Vein Thrombosis in Neonate With Umbilical Catheter

Start date: December 20, 2023
Phase:
Study type: Observational

The aim of this study is to identify incidence of portal vein thrombosis after umbilical catheter and to identify the risk factor of this condition ,location of PVT and prognosis of PVT.

NCT ID: NCT06149533 Not yet recruiting - Cancer Clinical Trials

Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients

Thrombosis
Start date: November 30, 2023
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of edoxaban in the prevention of tumor catheter-related thrombosis (CVC/PICC) in high-risk patients

NCT ID: NCT06122753 Not yet recruiting - Portal Hypertension Clinical Trials

Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis

Start date: January 2024
Phase: N/A
Study type: Interventional

Portal vein thrombosis (PVT) can lead to a further increase in portal venous pressure and increase the risk of rebleeding. Whether patients with acute esophagogastric variceal bleeding with occlusive PVT benefit from preemptive TIPS is still controversial. The present study is directed at comparing the outcome of patients with acute variceal bleeding with occlusive PVT treated by standard therapy (vasoactive drugs + endoscopic variceal ligation) with or without preemptive TIPS (performed during the first 1-3 days after endoscopic procedure). The primary outcome is survival free of variceal rebleeding at 6 weeks from inclusion.

NCT ID: NCT06117488 Not yet recruiting - Clinical trials for Portal Vein Thrombosis

Risk Factors and Management Outcome of Chronic Portal Vein Thrombosis in Children

Start date: November 1, 2023
Phase:
Study type: Observational

The aim of study is to evaluate different etiological and risk factors that lead to chronic portal vein thrombosis and to delineate a management plan for chronic portal vein thrombosis in children.

NCT ID: NCT06094387 Not yet recruiting - Thrombosis, Venous Clinical Trials

The Use of Thrombin Generation Assay in Detection of Central Line Related Thrombosis (CRT) in Critically Ill Patients

THROM-CRIT
Start date: January 1, 2024
Phase:
Study type: Observational [Patient Registry]

To study thrombin generation parameters in critically ill patients with and without central line related thrombosis (CRT).